What we're reading, March 3, 2016: additional funding for the opioid abuse bill was shot down in the Senate; Donald Trump releases his plan to replace Obamacare; and Christine Cassel, MD, discusses designing a new medical school.
Additional funding to combat heroin and prescription drug abuse was shot down in the Senate. Democrats lost their bid to add $600 million to a bill created to stop the growing substance abuse epidemic, but the party said it won’t block the legislation as a result of the funding battle, reported The Washington Post. The extra money would have gone to new opioid abuse programs being created by the bill and while 5 Republicans joined the Democrats to vote for the additional funds, they did not have enough votes overall.
Presidential candidate Donald Trump has released his own plan for replacing the Affordable Care Act (ACA). The Republican front-runner has included several ideas that align with conservative proposals, but the plan has few details about how his proposals would work, according to POLITICO. Trump’s plan would keep the ACA provision that insurers cannot deny coverage to individuals with pre-existing medical conditions, but he would do away with the individual mandate.
In an interview with Hospitals & Health Networks, Christine Cassel, MD, who has stepped down from her leadership position with the National Quality Forum to build the new Kaiser Permanente School of Medicine, discusses how one designs a medical school from scratch. One of the things she talked about was taking a more personalized approach with smaller classes to combat burnout and depression and focus on student wellness.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More